305 related articles for article (PubMed ID: 11935302)
1. The role of neoadjuvant chemotherapy and interval laparotomy in advanced ovarian cancer.
Huober J; Meyer A; Wagner U; Wallwiener D
J Cancer Res Clin Oncol; 2002 Mar; 128(3):153-60. PubMed ID: 11935302
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemotherapy in ovarian cancer.
Park TW; Kuhn WC
Expert Rev Anticancer Ther; 2004 Aug; 4(4):639-47. PubMed ID: 15270667
[TBL] [Abstract][Full Text] [Related]
3. Primary surgery or neoadjuvant chemotherapy followed by interval debulking surgery in advanced ovarian cancer.
Vergote I; Amant F; Kristensen G; Ehlen T; Reed NS; Casado A
Eur J Cancer; 2011 Sep; 47 Suppl 3():S88-92. PubMed ID: 21944035
[TBL] [Abstract][Full Text] [Related]
4. Residual cancer stem cells after interval cytoreductive surgery following neoadjuvant chemotherapy could result in poor treatment outcomes for ovarian cancer.
Lim MC; Song YJ; Seo SS; Yoo CW; Kang S; Park SY
Onkologie; 2010; 33(6):324-30. PubMed ID: 20523098
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of postoperative morbidities in patients with advanced epithelial ovarian cancer treated with neoadjuvant chemotherapy and delayed primary surgical debulking.
Le T; Alshaikh G; Hopkins L; Faught W; Fung MF
Ann Surg Oncol; 2006 Dec; 13(12):1711-6. PubMed ID: 17009146
[TBL] [Abstract][Full Text] [Related]
6. [Neoadjuvant chemotherapy in the treatment of ovarian cancer].
Lehoczky O
Orv Hetil; 2005 Sep; 146(38):1951-5. PubMed ID: 16238247
[TBL] [Abstract][Full Text] [Related]
7. The position of neoadjuvant chemotherapy within the treatment of ovarian cancer.
Van Gorp T; Amant F; Neven P; Berteloot P; Leunen K; Vergote I
Minerva Ginecol; 2006 Oct; 58(5):393-403. PubMed ID: 17006426
[TBL] [Abstract][Full Text] [Related]
8. Preliminary results of neoadjuvant chemotherapy with paclitaxel and cisplatin in patients with advanced epithelial ovarian cancer who are inadequate for optimum primary surgery.
Lee SJ; Kim BG; Lee JW; Park CS; Lee JH; Bae DS
J Obstet Gynaecol Res; 2006 Feb; 32(1):99-106. PubMed ID: 16445534
[TBL] [Abstract][Full Text] [Related]
9. [Ovarian cancer].
Onda T
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1735-9. PubMed ID: 18030006
[TBL] [Abstract][Full Text] [Related]
10. [Secondary debulking after dose-intensified chemotherapy of ovarian carcinoma].
Meier W; Gropp M; Burges A; Hepp H
Praxis (Bern 1994); 1999 Mar; 88(12):519-25. PubMed ID: 10235027
[TBL] [Abstract][Full Text] [Related]
11. Second-look laparotomy in ovarian cancer.
Creasman WT
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S122-7. PubMed ID: 7835795
[TBL] [Abstract][Full Text] [Related]
12. The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer.
Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Aghajanian C; Barakat RR; Chi DS
Gynecol Oncol; 2008 Feb; 108(2):276-81. PubMed ID: 18063020
[TBL] [Abstract][Full Text] [Related]
13. Role of chemotherapy in the management of epithelial ovarian cancer.
Reed NS; Sadozye AH
Expert Rev Anticancer Ther; 2005 Feb; 5(1):139-47. PubMed ID: 15757446
[TBL] [Abstract][Full Text] [Related]
14. Results of interval debulking surgery compared with primary debulking surgery in advanced stage ovarian cancer.
Morice P; Dubernard G; Rey A; Atallah D; Pautier P; Pomel C; Lhommé C; Duvillard P; Castaigne D
J Am Coll Surg; 2003 Dec; 197(6):955-63. PubMed ID: 14644284
[TBL] [Abstract][Full Text] [Related]
15. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
[TBL] [Abstract][Full Text] [Related]
16. [New approaches to the treatment of advanced ovarian cancer].
Ivanov S
Akush Ginekol (Sofiia); 2006; 45(4):20-3. PubMed ID: 16889195
[TBL] [Abstract][Full Text] [Related]
17. Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy.
Petit T; Velten M; d'Hombres A; Marchal C; Montbarbon X; Mornex F; Quetin P; Gérard JP; Romestaing P; Carrie C
Gynecol Oncol; 2007 Jan; 104(1):104-8. PubMed ID: 16987544
[TBL] [Abstract][Full Text] [Related]
18. [Early debulking surgery after chemotherapy in advanced cancer of the ovary].
de Gramont A; Pigné A; Louvet C; Sezeur A; Marpeau L; Vaillant JC; Cady J; Varette C; Demuynck B; Couturier JY; Lagadec B; Milliez J; Barrat J; Krulik M
Ann Chir; 1997; 51(10):1069-76. PubMed ID: 10868028
[TBL] [Abstract][Full Text] [Related]
19. Surgical debulking before or after chemotherapy: stemming the tide on ovarian cancer recurrence.
Rueda BR; Tilly JL; Schorge JO
Onkologie; 2010; 33(6):286-7. PubMed ID: 20523089
[No Abstract] [Full Text] [Related]
20. [Prognostic factors of ovarian cancer].
Ochiai K
Gan To Kagaku Ryoho; 2006 Dec; 33(13):2014-9. PubMed ID: 17197745
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
